- Home
- GMS vs HCM Comparison
GMS vs HCM Comparison
Compare GMS & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMS
- HCM
- Stock Information
- Founded
- GMS 1971
- HCM 2000
- Country
- GMS United States
- HCM Hong Kong
- Employees
- GMS N/A
- HCM N/A
- Industry
- GMS
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- GMS
- HCM Health Care
- Exchange
- GMS Nasdaq
- HCM Nasdaq
- Market Cap
- GMS 3.0B
- HCM 2.6B
- IPO Year
- GMS 2016
- HCM N/A
- Fundamental
- Price
- GMS $72.64
- HCM $14.90
- Analyst Decision
- GMS Hold
- HCM Hold
- Analyst Count
- GMS 7
- HCM 1
- Target Price
- GMS $80.57
- HCM $19.00
- AVG Volume (30 Days)
- GMS 605.8K
- HCM 85.0K
- Earning Date
- GMS 03-06-2025
- HCM 03-19-2025
- Dividend Yield
- GMS N/A
- HCM N/A
- EPS Growth
- GMS N/A
- HCM N/A
- EPS
- GMS 3.66
- HCM 0.04
- Revenue
- GMS $5,592,971,000.00
- HCM $630,201,000.00
- Revenue This Year
- GMS $3.58
- HCM $28.98
- Revenue Next Year
- GMS $2.88
- HCM $20.41
- P/E Ratio
- GMS $20.18
- HCM $69.52
- Revenue Growth
- GMS 3.71
- HCM N/A
- 52 Week Low
- GMS $65.88
- HCM $12.84
- 52 Week High
- GMS $105.54
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- GMS 37.20
- HCM 46.43
- Support Level
- GMS $71.51
- HCM $14.00
- Resistance Level
- GMS $76.30
- HCM $15.57
- Average True Range (ATR)
- GMS 1.69
- HCM 0.45
- MACD
- GMS 0.43
- HCM -0.12
- Stochastic Oscillator
- GMS 35.32
- HCM 29.55
About GMS GMS Inc.
GMS Inc is a distributor of specialty building products including wallboard, suspended ceiling systems, ceilings, steel framing, and other complementary building products. The company serves its products to commercial new construction, commercial repair and remodel, residential new construction, and residential repair and remodel (R&R). Its geographical segment is Central, Midwest, New York, Northeast, Southern, Southeast, Southwest, Western and Canada, and Ames. The company generates maximum revenue from Wallboard products.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.